Anti-pd-1 antibodies and methods of use thereof
AssigneeRinat Neuroscience Corp.
InventorsYasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
Life of this patent
Estimating the term…
Abstract
The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
Claims16
1-38. (canceled)
A method for treating cancer in a subject in need thereof, the method comprising administering to the subject (1) an effective amount of an isolated antagonist antibody that specifically binds to PD-1 and comprises:
- a heavy chain variable region (VH) comprising a VH complementarity determining region one (CDR1), VH CDR2, and VH CDR3 of the VH having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 4;
- SEQ ID NO:
- 5;
- and SEQ ID NO:
- 6;
- and
- a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3 of the VL having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2;
- SEQ ID NO:7;
- SEQ ID NO:
- 8;
- and SEQ ID NO:
- 9,
- and (2) an effective amount of a vaccine capable of eliciting an immune response against cells of the cancer.
A method for enhancing the immunogenicity or therapeutic effect of a vaccine administered to a subject for the treatment of cancer, the method comprising administering to the subject receiving the vaccine an effective amount of an isolated antagonist antibody that specifically binds to PD-1 and comprises:
- a heavy chain variable region (VH) comprising a VH complementarity determining region one (CDR1), VH CDR2, and VH CDR3 of the VH having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 4;
- SEQ ID NO:
- 5;
- and SEQ ID NO:
- 6;
- and
- a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3 of the VL having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2;
- SEQ ID NO:7;
- SEQ ID NO:
- 8;
- and SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.